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Abstract The classical Bowman-Birk inhibitor from soya re- 
tards strongly the hydrolysis of elastin catalyzed by leukocyte 
elastase, cathepsin G and a mixture of both. The inhibitory effect 
is practically unaffected by both the adsorption of the enzymes 
on elastin and prolongation of the enzymatic reaction. 
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1. Introduction 
Serine proteinases from granule fraction of human polymor- 
phonuclear leukocytes, viz. elastase (HLE) and cathepsin G 
(HLCG), hydrolyze several important structural proteins of 
connective tissue including elastin, collagen (types I-V, IX, X, 
XI), fibronectin, proteoglycans [1,2]. It is commonly believed 
that the hydrolysis of elastin by HLE plays a role in the destruc- 
tion of connective tissue in some inflammatory diseases, such 
as lung emphysema, arthritis, etc. [3,4]. Modulation of the 
elastinolytic activity of HLE has been a focus of many investi- 
gations on therapeutically useful inhibitors [3,4]. 
HLCG has a low elastinolytic activity [5,6] but is able to 
stimulate the HLE-catalyzed hydrolysis of elastin from differ- 
ent tissues [6-8]. The stimulation factor (Fst) reaches 2.0-2.6 in 
hydrolysis of bovine neck ligament elastin [6-7] and 1.4-2.9 [7] 
or 7.2 [6] in hydrolysis of elastin from human lung (the data are 
shown for [HLE]/[HLCG] = 1 : 2; F~t = (VHLE.HLCG-- VHLCG)/ 
VHLE, where VHLE, VHLCG and VHLE+r~LCG are the initial rates 
of elastinolysis catalyzed by HLE, HLCG and the mixture of 
the both). The synergistic action of two enzymes on elastin 
stimulates search for inhibitors which suppress the elastinolytic 
activity of the both proteinases. 
BBI is a 8 kDa protein with two reactive sites. One site binds 
trypsin, while the other shows affinity to chymotrypsin-like 
enzymes [9] (including HLCG) and HLE [10]. Earlier we 
showed that BBI is an effective reversible competitive inhibitor 
of HLE and HLCG in the reactions with synthetic substrates 
of low molecular weight [10~12]. According to Bieth [13], two 
parameters, the association rate constant, kon, and the inhibi- 
tion constant, K, affect the efficiency of the inhibitors in 
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Abbreviations." BBI, classical soybean Bowman-Birk protease inhibitor; 
BPTI, basic pancreatic trypsin inhibitor; DMSO, dimethyl sulfoxide; 
HLE, human leukocyte lastase; HLCG, human leukocyte cathepsin 
G; MeOSuc-Ala-Ala-Pro-Val-pNA, methoxysuccinyl-Ala-Ala-Pro- 
Val-p-nitroanilide; ~-PI, ~-proteinase inhibitor; Suc-Ala-Ala-Pro- 
Phe-pNA, succinyl-Ala-Ala-Pro-Phe-p-nitroanilide; F~, stimulation 
factor. 
vivo. BBI interacts with HLE with ko, = 3.5x 10 4 M-~.s -~ 
and K~ = 2.0 nM [10,12] and with HLCG with 
kon = 6.4 x 10 6 M -1 '  s - I  and Ki = 1.2 nM [10,11]. These values 
suggest hat BBI might be an effective inhibitor of elastin hy- 
drolysis catalyzed by HLE and HLCG. This work was aimed 
at finding experimental evidence for this hypothesis. 
2. Materials and methods 
2.1. Materials 
Bovine neck ligament elastin, Brij-35, DMSO, HEPES, MeOSuc- 
Ala-Ala-Pro-Val-pNA, ~-PI, Suc-Ala-Ala-Pro-Phe-pNA and Tris- 
HCI (Sigma, USA); CM-Sephadex C-50 and BrCN-activated Sepha- 
rose 4B (Pharmacia, Sweden); Triton X-100 and Dextran T-500 (Loba 
Chemic, Austria), Bovine trypsin with 49% content of active sites (ti- 
trated with p-nitrophenyl p-guanidinobenzoate [14]) (Spofa, Czechia); 
BPTI preparation 'Gordox' (Gedeon Richter, Hungary). 
2.2. BBI isolaton 
BBI was isolated from soya variety VNIIS-2 by using a modified 
method of Odani and lkenaka [15] described elsewhere [10]. The inhib- 
itor was quantitated by direct itration with active site-titrated trypsin 
and was ca. 100% active with respect o total protein. 
2.3. HLE and HLCG isolation 
HLE and HLCG were purified from healthy donor blood using a 
slightly modified method of Baugh and Travis [16]. The procedure 
included affinity chromatography onBPTI-Sepharose 4B and ion-ex- 
change chromatography onCM-Sephadex C-50. BPTI-Sepharose 4B 
was prepared by immobilization fdesalted and lyophilized 'Gordox' 
on BrCN-activated Sepharose 4B [16]. 
Titration of HLE and HLCG with standartized BBI and ~-PI re- 
vealed 93-95% and 75-80% activity of the enzymes, respectively. Spe- 
cific activity was 11.2 and 4.2 pmol/min.mg for HLE and HLCG, 
respectively (see section 2.5). HLCG preparation contained no admix- 
ture of HLE. 
2.4. Protein determination 
Protein was determined by the Lowry routine [17]. 
2.5. Enzyme assays 
HLE was determined spectrophotometrically by measuring the rate 
of generation ofp-nitroaniline (e4~0 =8,800 M -h -cm -~ [18]) during the 
hydrolysis of the specific substrate MeOSuc-Ala-Ala-Pro-Val-pNA at 
25°C. The reaction mixture contained the substrate (0.32 raM) and the 
enzyme in the concentration range 10-8-10-7M in 0.1 M HEPES buffer, 
pH 7.5, 0.5 M NaC1, 0.005% Triton X-100 and 10% DMSO. 
HLCG was assayed spectrophotometrically in a similar way using 
SucAla-Ala-Pro-Phe-pNA as substrate. The reaction mixture contained 
0.1 mM substrate and the enzyme in the concentration range 10 -8- 
5 × 10 -7 M in 0.1 M HEPES, pH 7.5, 0.5 M NaCI, 0.005% Triton X-100 
and 10% DMSO. 
All spectrophotometric measurements were performed on a 
Shimadzu UV-265 FM spectrophotometer. 
2.6. Elastin hydrolysis 
The hydrolysis was carried out at 37°C in 0.05 M Tris buffer, pH 7.4, 
contaning 0.15 M NaC1 with permanent agitation as described else- 
where [6]. The absorbance of supernatant at 280 nm was used to eval- 
uate the concentration of soluble elastin fragments released in the 
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course of enzymatic hydrolysis [6]. Slope V = A28olt was taken as a rate 
of elastin hydrolysis (solubilization). The rate depends linearly on the 
enzyme concentration at 0.5-2.4 pM for HLE and HLCG and for the 
mixture of the both at concentration ratio [HLE]/[HLCG] from 1 : 1 to 
1:2. 
In experiments without preadsorption f the enzymes on elastin, the 
reagents were mixed in the following order: elastin, buffer, inhibitor, 
enzymes. Preadsorption of the enzymes was achived by incubating 
elastin and enzymes in a buffer for 5 rain at 37°C with agitation prior 
to addition of the inhibitor. As it was noticed earlier for HLE [19,20] 
and shown by us for HLCG, the absorption iscomplete in a matter of 
5 min. 
3. Results and discussion 
3.1. Inhibition of  elastinolysis catalyzed by HLE and HLCG 
without preadsorption of  the enzymes on elastin 
When HLE and BBI are simultaneously added into a suspen- 
sion of elastin, the elastinolytic activity of HLE decreases con- 
tinuously with increasing BBI concentration (Fig. 1, curve 1). 
Complete inhibition is observed at the [I]J[E]o ratio as low as 
5. With eglin C, i.e. one of the best exogenic inhibitors of HLE, 
the elastinolysis completely inhibited at [I]o/[E]o = 12.5 [21]. 
For the HLCG-catalyzed hydrolysis of elastin, complete in- 
hibition is reached at a higher BBI concentration. More than 
95% of the elastinolytic activity is inhibited at [I]o/[E]o -- 20 
(Table 1). 
Apparently, as in the case of other reversible protein inhib- 
itors of HLE [19,21], BBI, on administration, immediately 
forms a complex with HLE or HLCG, which is stable in the 
presence of elastin. Preferable complexation of HLE or HLCG 
with BBI, rather than with elastin, is suggested by analysis of 
the rates of these three processes. Half-association times, t,/2, 
calculated as ln2/[I]o'kon at [I]o >> [E]o, equal 1.9 and 0.01 s for 
the BBI binding to HLE and HLCG, respectively, at [I]o = 10 
/aM. The complex between HLE and elastin is formed slower, 
tj/2 = 72.0 s [21]. There is no data available on kinetics of inter- 
action between HLCG and elastin. 
Practically irreversible inhibition of HLE and HLCG by BBI 
under these conditions ([E]o = 0.6-1.6 /tM, [E]JK i = 500- 
1,000) is in good agreement with the theory of Bieth [13]. The 
stability of the E1 complex in the presence of elastin was addi- 
tionally confirmed by the following experiment. Elastin (l 0 mg) 
was administered to an equimolar mixture of HLE and BBI (1 
/aM) and incubated for 30 min. There was no elastin hydrolysis 
after 4 h. 
As mentioned earlier [6-8], HLCG was able to stimulate the 
hydrolysis of elastin by HLE. According to our data Fst 
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Fig. 1. Inhibition of HLE - catalyzed hydrolysis of elastin by BBI. 
Curve 1, without preadsorption. Curve 2, with preadsorption f HLE 
on elastin: the inhibitor was added 5 rain (e) and 30 rain (A) after the 
start of elastinolysis. [HLE]o = 1 pM, 100% = elastinolytic activity of 
HLE without he inhibitor. 
increases linearly with [HLCG] in the range 0.3-2.0 /aM 
([HLE] = 1.0/aM). At ratios [HLE]/[HLCG] = 1 : 1 and 1:2 Fst 
equals 1.35 and 2.0, respectively. These values of Fst are in 
accord with the data reported by other authors for hydrolysis 
of bovine neck ligament elastin [6-8]. 
BBI supresses effectively the bi-enzyme lastinolysis under 
the stimulating conditions (Table 1). An increase in the enzyme 
ratio [HLE]/[HLCG] from 1:1 to 1:1.5 does not practically 
affect the degree of inhibition at [BBI] = 100/aM. 
3.2. BBI inhibition of  elastin-bound HLE and HLCG 
All the above data refer to the systems in which the enzymes 
are added simultaneously or after the inhibitor. The results 
might be different, if the enzymes preadsorbed on elastin are 
used. It is known, for example, that adsorption of HLE on 
elastin protects the enzyme from the action of physiological 
~I-PI. The residual enzymatic activity equals 25% and does not 
decrease further on addition the inhibitor [19]. Apparently, the 
steric hindrance disfavors the association between the inhibitor 
and the enzyme adsorbed on insoluble substrate. In contrast, 
low molecular weight protein inhibitors, secretory leukocyte 
Table 1 
Suppression by BBI of elastinolysis catalyzed by leukocyte proteinases 
[HLE]o, pM [HLCG]o, pM [I]o, pM Residual elastolytic activity (%) 
Without preadsorption f
enzymes of elastin 
Without preadsorption f
enzymes of elastin 
0.0 0.9 0.0 100 
0.0 0.9 20.0 5 
0.0 0.9 100.0 0 
0.6 0.6 0.0 100 
0.6 0.6 20.0 1 
O.6 O.6 5O.O 0 
0.6 0.6 100.0 0 
0.6 0.9 0.0 100 
0.6 0.9 100.0 0 
100 
11 
8 
100 
7 
100 
10 
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Fig. 2. Inhibition of HLE (panel A) and (HLE+HLCG) (panel B) 
mediated hydrolysis of elastin by BBI. The points of inhibitor admini- 
stration are shown by arrows. Hydrolysis of elastin in the absence of 
the inhibitor (©); hydrolysis of elastin after addition of inhibitor (e). 
A: [HLE]o = 1.2 ,uM; B: [HLE]o = 0.6/~M, [HLCG]o = 0.6 ,uM. 
proteinase inhibitor and eglin C, inhibit HLE in solution and 
on the support in a similar way [19,21]. 
To study the inhibition of elastin-bound HLE and HLCG we 
investigated the adsorption of enzymes as it was described by 
Bruch and Bieth [19]. The adsorption of HLE is a function of 
the ratio [E]o/[S]o in the range of HLE concentrations used. 
HLE is adsorbed on elastin almost completely (more than 90%) 
only at [E]o/[S]o lower 0.04 nmol HLE per mg elastin. This 
differs from the data reported elsewhere [19,22] where the H LE 
activity was completely adsorbed at 0.2~0.25 nmol HLE per mg 
elastin. The discrepancy may be due to variable properties of 
elastin from different sources or due to using different isolation 
procedures [19, 22]. Sorption capacity of elastin for HLCG is 
higher than that for HLE and equals 0.2 nmol HLCG per mg 
elastin. 
Further studies are performed with the proteinases com- 
pletely adsorbed on elastin. Administration of BBI into these 
systems allows to reach almost complete inhibition of elastinol- 
ysis but higher concentrations of BBI than in the case of simul- 
taneous addition of enzymes and inhibitor are required. A 
complete suppression of elastin-bound HLE is reached only at 
the ratio [I]o/[E]o = 15-20 (Fig. 1, curve 2). For HLCG ad- 
sorbed on elastin, 90% of elastinolytic activity is inhibited at 
[I]J[E]o = 20 (Table 1). Five-fold enhancement of the BBI con- 
centration decreases the residual HLCG activity by 3% only. 
On addition of BBI to a mixture of both proteinases pread- 
sorbed on elastin (Table 1) residual activity increases with en- 
hancement of HLCG concentration. 
Likewise other low molecular weight protein inhibitors [19] 
BBI is, apparently, able to induce the dissociation of HLE- and 
HLCG-elastin complexes to form the El complex. However, a 
small fraction of HLCG bound to elastin is not available to the 
inhibitor. 
One of the possible factors affecting the efficiency of the 
inhibition is the duration of preincubation of proteinases with 
elastin. Hydrolysis of elastin by HLE could be described by the 
following kinetic scheme [21]: 
(1) (2) (3) 
E + S ~ ES~ ES"---~ E + P 
The rapid and reversible complex formation (1) is followed 
by slow reversible 'isomerization' (2) of the encounter complex. 
Steady-state elastinolytic reaction (3) can then occur. Steps (1) 
and (2) do not involve elastin degradation [21]. In our experi- 
ments HLE is usually preadsorbed on elastin for 3-5 min as 
recommended lsewhere [19-22]. The incubation time is shorter 
than the time (t99%) required to complete the formation of ES" 
(/99% ---- 8.4 min) [21]. Addition of an inhibitor during the forma- 
tion of complex ES induces its rapid dissociation and thereby 
suppression of elastinolysis effective. 
Longer interaction between HLE and elastin prior to admin- 
istrating the inhibitor can reduce the inhibitory effect. This 
phenomenon was observed with eglin C and human pancreatic 
elastase [23]. The inhibiting efficiency decreased consequently 
from 95 to 75% on addition of the inhibitor after 10, 20, 60, 90 
min from the begining of the elastinolysis. The effect was ac- 
counted for by the fact that a fraction of the enzyme became 
more strongly bound to elastin as the reaction proceeded and 
thus was not available to the inhibitor [23]. Similar experiments 
were performed with BBI and HLE as well as with BBI and the 
mixture of both proteinases. The inhibition degree is more than 
95% in the case of HLE-catalyzed elastinolysis when the inhib- 
itor is added 5 or 90 min after the start (Fig. 2, panel A). The 
dependency of the degree of inhibition on the BBI concentra- 
tion was obtained for two periods of time 30 and 60 rain. This 
is practically the same as in the case where BBI was added 
5 min after initiation (Fig. 1, curve 2). When elastinolysis 
catalyzed by the HLE and HLCG mixture (Fig. 2, panel B) the 
inhibition is equal to 90% on addition of BBI both immediately 
after adsorption and after 30-120 min from the start of the 
reaction. These results uggest that BBI is effective in suppress- 
ing elastinolysis catalyzed by leukocyte proteinases regardless 
a step of elastin solubilization. 
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